Meridian Bioscience (NASDAQ:VIVO) reported its Q2 earnings results on Friday, May 6, 2022 at 08:00 AM.
Here's what investors need to know about the announcement.
Earnings
Meridian Bioscience beat estimated earnings by 40.43%, reporting an EPS of $0.66 versus an estimate of $0.47.
Revenue was up $25.97 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.1 which was followed by a 12.16% increase in the share price the next day.
Here's a look at Meridian Bioscience's past performance:
| Quarter | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 |
|---|---|---|---|---|
| EPS Estimate | 0.25 | 0.20 | 0.31 | 0.48 |
| EPS Actual | 0.35 | 0.23 | 0.22 | 0.56 |
| Revenue Estimate | 70.29M | 68.40M | 77.22M | 84.48M |
| Revenue Actual | 88.34M | 76.20M | 63.51M | 85.26M |
To track all earnings releases for Meridian Bioscience visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
